Dr. Agarwal on the TALAPRO-2 Trial in mCRPC
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.
Thus far, in part 1 of the TALAPRO-2 trial, data showed that the optimal 0.5 mg dose of talazoparib (Talzenna) was found to be very safe and was associated with preliminary efficacy when in combination with enzalutamide (Xtandi), Agarwal explains.
The ultimate goal of part 2 of this study is to improve survival in these patients, not only in terms of radiographic progression-free survival, but also overall survival. The trial is enrolling more than 800 patients worldwide, and investigators hope to see encouraging data that will change the standard of care for this patient population.
